Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Income from Continuing Operations for 7 consecutive years, with -$57.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations fell 7.76% year-over-year to -$57.3 million; the trailing twelve-month figure through Jun 2026 stood at -$294.9 million (up 1.85% YoY), and the FY2025 full-year result was -$312.8 million, up 42.83% from the prior year.
• Income from Continuing Operations improved to -$57.3 million in Q2 2026 per DNA's latest filing, from -$76.1 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$53.2 million in Q2 2025 and bottomed at -$670.6 million in Q2 2022.
• Historically, Income from Continuing Operations has averaged -$221.0 million across 5 years, with a median of -$169.5 million in 2022.
• The widest YoY moves for Income from Continuing Operations: up 89.22% in 2022, down 1131.22% in 2022.
• Over 5 years, Income from Continuing Operations stood at -$173.1 million in 2022, then decreased by 22.31% to -$211.7 million in 2023, then jumped by 49.2% to -$107.5 million in 2024, then climbed by 24.91% to -$80.8 million in 2025, then climbed by 29.02% to -$57.3 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$57.3 million, -$76.1 million, and -$80.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.